Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 12, 2017, Pages 951-964

  Ueki, Kohjiro ^a,b   Sasako, Takayoshi ^b,c   Okazaki, Yukiko ^b   Kato, Masayuki ^d   Okahata, Sumie ^e   Katsuyama, Hisayuki ^f   Haraguchi, Mikiko ^b   Morita, Ai ^b   Ohashi, Ken ^g   Hara, Kazuo ^h   Morise, Atsushi ⁱ   Izumi, Kazuo ^a   Ishizuka, Naoki ^j   Ohashi, Yasuo ^k   Noda, Mitsuhiko ^l   Kadowaki, Takashi ^b,c   Haneda, Masakazu ^m   Iwashima, Yasunori ^m   Suda, Toshihiro ^m   Tamasawa, Naoki ^m   Daimon, Makoto ^m   Satoh, Jo ^m   Takebe, Noriko ^m   Ishigaki, Yasushi ^m   Watanabe, Tsuyoshi ^m   Satoh, Hiroaki ^m   Kasai, Kikuo ^m   Aso, Yoshimasa ^m   Ishibashi, Shun ^m   Katayama, Shigehiro ^m   Ishikawa, San e ^m   Kakei, Masafumi ^m   Namai, Kazuyuki ^m   Hashimoto, Naotake ^m   Suzuki, Yoshifumi ^m   Onishi, Shunichiro ^m   Yokote, Koutaro ^m   Matsuda, Masafumi ^m   Masuzawa, Masahiro ^m   Hayashi, Yoichi ^m   Saito, Satoshi ^m   Ogihara, Norikazu ^m   Ishihara, Hisamitsu ^m   Tajima, Naoko ^m   Utsunomiya, Kazunori ^m   Shimada, Akira ^m   Itoh, Hiroshi ^m   Kawamori, Ryuzo ^m   Watada, Hirotaka ^m   Hayashi, Michio ^m   Mori, Yasumichi ^m   Shiba, Teruo ^m   Isogawa, Akihiro ^m   Sakura, Hiroshi ^m   Odawara, Masato ^m   Tobe, Kazuyuki ^m   Tsukamoto, Kazuhisa ^m   Yamauchi, Toshimasa ^m   Teramoto, Tamio ^m   Hirata, Yukio ^m   Uchimura, Isao ^m   Ogawa, Yoshihiro ^m   Yoshino, Gen ^m   Hirose, Takahisa ^m   Kajio, Hiroshi ^m   Atsumi, Yoshihito ^m   Oikawa, Yoichi ^m   Araki, Atsushi ^m   Ueki, Akio ^m   Ohno, Atsushi ^m   Kitaoka, Masafumi ^m   Fujita, Yoshikuni ^m   Moriya, Tatsumi ^m   Tojo, Taiki ^m   Shichiri, Masayoshi ^m   Suzuki, Daisuke ^m   Toyoda, Masao ^m   Hamano, Kumiko ^m   Komi, Rieko ^m   Terauchi, Yasuo ^m   Kuzuya, Nobuaki ^m   Yamada, Masayo ^m   Takamura, Toshinari ^m   Imura, Mitsuo ^m   Tanaka, Hiroshi ^m   Hayashi, Masayuki ^m   Kato, Yasuhisa ^m   Itoh, Mitsuyasu ^m   Suzuki, Atsushi ^m   Nakayama, Mikihiro ^m   Sano, Takahisa ^m   Nakashima, Eitaro ^m   Sumida, Yasuhiro ^m   Yano, Yutaka ^m   Tanaka, Tsuyoshi ^m   Murata, Kazuya ^m   Kashiwagi, Atsunori ^m   Maegawa, Hiroshi ^m   Kono, Shigeo ^m   Inagaki, Nobuya ^m   Kosugi, Keisuke ^m   Yasuda, Tetsuyuki ^m   Yoshimasa, Yasunao ^m   Kishimoto, Ichiro ^m   Sato, Toshihiko ^m   Hosoi, Masayuki ^m   Yamasaki, Tomoyuki ^m   Matsuhisa, Munehide ^m   Shimomura, Iichiro ^m   Taniguchi, Ataru ^m   Kuroe, Akira ^m   Kurose, Takeshi ^m   Ohara, Takeshi ^m   Sakaguchi, Kazuhiko ^m   Namba, Mitsuyoshi ^m   Kaku, Kohei ^m   Fujiwara, Masazumi ^m   Shimizu, Ikki ^m   Ono, Keizo ^m   Ebisui, Osamu ^m   Tanizawa, Yukio ^m   Okada, Yosuke ^m   Natori, Shoichi ^m   Kodera, Takehiko ^m   Sato, Naoichi ^m   Ide, Makoto ^m   Yamada, Kentaro ^m   Umeda, Fumio ^m   Eto, Tomoaki ^m   Mimura, Kazuo ^m   Hiramatsu, Shinsuke ^m   Inoue, Tomoaki ^m   Takei, Ryoko ^m   Ogo, Atsushi ^m   Eguchi, Katsumi ^m   Kawasaki, Eiji ^m   Koide, Yuji ^m   Araki, Eiichi ^m   Jinnouchi, Hideaki ^m   Yamamoto, Hiroaki ^m   Motoyoshi, Mitsutaka ^m   Hiyoshi, Toru ^m   Tanaka, Yasushi ^m   Momoki, Tadahisa ^m   Sato, Koichiro ^m   Yoneyama, Akihiko ^m   Ito, Kenichi ^m   Sobajima, Hiroshi ^m   Ikegami, Hiroshi ^m   Ikeda, Masaki ^m   Ikeda, Hiroki ^m   Takahashi, Kenji ^m   Makino, Hirofumi ^m   Ueda, Yasuo ^m   Nakazato, Masamitsu ^m   more..

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^f National Center for Global Health and Medicine   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL   (Japan)

^h JICHI MEDICAL UNIVERSITY   (Japan)

ⁱ JCHO Tokyo Takanawa Hospital   (Japan)

^j CANCER INSTITUTE HOSPITAL   (Japan)

^k CHUO UNIVERSITY   (Japan)

^l SAITAMA MEDICAL UNIVERSITY   (Japan)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; ORAL ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA;

ADULT; AGE; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CAROTID ARTERY STENTING; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; JAPAN; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX; SYSTOLIC BLOOD PRESSURE; TRANSLUMINAL CORONARY ANGIOPLASTY; CAUSALITY; CLINICAL TRIAL; EARLY INTERVENTION; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PROCEDURES; TREATMENT OUTCOME; TRENDS;

AGED; CARDIOVASCULAR DISEASES; CAUSALITY; DIABETES MELLITUS, TYPE 2; EARLY MEDICAL INTERVENTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

EID: 85033454556     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30327-3     Document Type: Article

References (37)

1. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364 (2011), 829–841.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
4. Ohkubo, Y, Kishikawa, H, Araki, E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28 (1995), 103–117.
5. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
6. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
7. Duckworth, W, Abraira, C, Moritz, T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
8. Desouza, CV, Bolli, GB, Fonseca, V, Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33 (2010), 1389–1394.
9. Tsujimoto, T, Yamamoto-Honda, R, Kajio, H, et al. Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients. Diabetes Care 37 (2014), 217–225.
10. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998), 713–720.
11. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007), 829–840.
12. Colhoun, HM, Betteridge, DJ, Durrington, PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004), 685–696.
13. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care 40:suppl 1 (2017), S75–S87.
14. Rydén, L, Grant, PJ, Anker, SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
15. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
16. Obara, F, Saitoh, S, Takagi, S, Shimamoto, K, Influence of hypertension on the incidence of cardiovascular disease in two rural communities in Japan: the Tanno-Sobetsu study. Hypertens Res 30 (2007), 677–682.
17. Tajima, N, Noda, M, Origasa, H, et al. Evidence-based practice guideline for the treatment for diabetes in Japan 2013. Diabetol Int 6 (2015), 151–187.
18. Sone, H, Tanaka, S, Tanaka, S, et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 96 (2011), 3448–3456.
19. Gæde, P, Vedel, P, Larsen, N, Jensen, GV, Parving, HH, Pedersen, O, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
20. Gæde, P, Lund-Andersen, H, Parving, HH, Pedersen, O, Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008), 580–591.
21. Gæde, P, Oellgaard, J, Carstensen, B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59 (2016), 2298–2307.
22. Ueki, K, Sasako, T, Kato, M, et al. Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. BMJ Open Diabetes Res Care, 4, 2016, e000123.
23. Yazaki, Y, Kadowaki, T, Combating diabetes and obesity in Japan. Nat Med 12 (2006), 73–74.
24. Pocock, SJ, Simon, R, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975), 103–115.
25. Gregg, EW, Li, Y, Wang, J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370 (2014), 1514–1523.
26. James, PA, Oparil, S, Carter, BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
27. Emdin, CA, Rahimi, K, Neal, B, Callender, T, Perkovic, V, Patel, A, Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
28. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 36:suppl 1 (2013), S11–S66.
29. Sone, H, Tanaka, S, Tanaka, S, et al. Leisure-time physical activity is a significant predictor of stroke and total mortality in Japanese patients with type 2 diabetes: analysis from the Japan Diabetes Complications Study (JDCS). Diabetologia 56 (2013), 1021–1030.
30. Kernan, WN, Viscoli, CM, Furie, KL, et al., for the IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
31. Perkovic, V, Heerspink, HL, Chalmers, J, et al., for the ADVANCE Collaborative Group. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83 (2013), 517–523.
32. de Galan, BE, Perkovic, V, Ninomiya, T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 20 (2009), 883–892.
33. Ismail-Beigi, F, Craven, T, Banerji, MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376 (2010), 419–430.
34. Griffin, SJ, Borch-Johnsen, K, Davies, MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378 (2011), 156–167.
35. Nakamura, J, Kamiya, H, Haneda, M, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 8 (2017), 397–410.
36. Hemmingsen, B, Lund, SS, Gluud, C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ, 343, 2011, d6898.
37. Holman, RR, Paul, SK, Bethel, MA, Matthews, DR, Neil, HA, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.